Rely on a single comprehensive genomic profile to optimize overall breast cancer treatment strategy.

Please log in for more information

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the Retina field I want to stay up to date with the Infectious Diseases field I want to stay up to date with the Pathologist Educator field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Agendia is a leading molecular diagnostics company focused on improving the quality of life for cancer patients by developing genomic tests to support physicians in making complex treatment decisions while reducing costs to the healthcare system. Our genomic tests are helping to achieve this goal with global guideline inclusion, as well as a growing customer base, including many major hospitals and clinical institutions. MammaPrint, our FDA-cleared test backed by the highest level of clinical evidence, paired with BluePrint, the only commercially available molecular subtyping test, enable physicians to confidently optimize a unique treatment strategy for each patient.

Pillar Biosciences’ oncoReveal™ CDx Pan-Cancer Solid Tumor IVD: A Rapid FDA Approved NGS Kit to Help Drive Actionable and Accessible Localized Testing.

10/23/2024 | Sponsored by Illumina